The Global Hepatic Encephalopathy (HE) Market, valued at USD 1.70 billion in 2023, is projected to reach USD 2.75 billion by 2032, growing at a CAGR of 5.50% from 2024 to 2032, according to a new in-depth report by Introspective Market Research.

Hepatic encephalopathy—a disabling neuropsychiatric complication of advanced liver disease—is gaining renewed clinical and commercial attention as cirrhosis prevalence surges worldwide. With over 112 million people globally living with decompensated cirrhosis (Global Burden of Disease Study, 2024), and up to 70% developing some form of HE during their disease course, the unmet need for effective, tolerable, and accessible therapies is escalating rapidly.

Market growth is being propelled by three converging forces:
✅ Rising incidence of chronic liver disease (driven by NAFLD/NASH, alcohol use disorder, and viral hepatitis),
✅ Adoption of non-invasive diagnostics (serum biomarkers, digital cognitive tools, AI-enhanced EEG), and
✅ Innovation beyond lactulose monotherapy—particularly combination regimens and gut-microbiome-targeted agents aimed at modulating the gut-liver-brain axis.

Quick Insights: Hepatic Encephalopathy Market at a Glance

• 2023 Market Size: USD 1.70 Billion
• 2032 Projected Value: USD 2.75 Billion
• CAGR (2024–2032): 5.50%
• Dominant Disease Segment: Overt Hepatic Encephalopathy (clinically apparent, high hospitalization burden)
• Leading Treatment Class: Lactulose (~52% market share), followed by Rifaximin combination therapy (fastest-growing segment)
• Top Route of Administration: Oral (85% share), owing to outpatient manageability and chronic dosing needs
• Largest Regional Market: North America (44.3% share in 2023), led by the U.S.
• Fastest-Growing Region: Asia Pacific — projected CAGR of 6.8%, driven by rising NASH, alcohol-associated cirrhosis, and improved HE recognition
• Key Players: Salix Pharmaceuticals (Bausch Health), AbbVie, Mallinckrodt Pharmaceuticals, Cosmo Pharmaceuticals, Hepion Pharmaceuticals, Eisai Co., Ltd., Zydus Lifesciences, Fresenius Kabi

If Lactulose Has Been the Standard for 50+ Years—Why Is the HE Market Now Accelerating?

The answer lies in a fundamental shift: HE is no longer viewed as an inevitable end-stage complication—but as a modifiable, preventable, and quantifiable condition.

Recent guidelines (AASLD/EASL 2024 update) now emphasize early-stage covert HE screening using validated psychometric tools (e.g., PHES, Stroop tests) or emerging digital biomarkers—allowing intervention before hospitalization or falls occur. Simultaneously, real-world evidence confirms that rifaximin + lactulose reduces HE recurrence by 58% and all-cause hospitalizations by 32% vs. lactulose alone—justifying premium pricing and broader insurance coverage.

Moreover, the pipeline is heating up: Hepion’s CRV431 (cyclophilin inhibitor), Cosmo’s SYN-010 (targeted rifaximin reformulation), and Eisai’s ammonia-lowering probiotic consortia are advancing through Phase II, signaling a move toward mechanism-based, not just ammonia-lowering, therapeutics.

“The HE market is transitioning from symptom suppression to system modulation,” says Dr. Ritu Kapoor, Principal Consultant, Neuro-Gastroenterology Hepatology Therapeutics Practice at Introspective Market Research.
“What’s changed is not just the science—but the economics. Payers now recognize that a USD 20/day HE regimen prevents a USD 35,000 hospital admission. That value equation is unlocking access in Medicaid, VA, and emerging-market formularies. The next frontier? Home-based monitoring via wearables and AI-driven cognitive decline alerts—turning HE from reactive crisis care into proactive chronic disease management.”

Regional Deep Dive: North America Leads, But APAC Holds the Growth Key

North America (44.3% Market Share)

The U.S. remains the revenue engine—fueled by:

• High diagnosis rates (HE listed in 68% of U.S. cirrhosis hospital discharges, per HCUP 2024)
• Strong reimbursement for Xifaxan® (rifaximin), now covered by 96% of Medicare Part D plans
• Integrated care models (e.g., Kaiser Permanente’s HE pathway) embedding screening into routine hepatology visits
• Robust clinical trial infrastructure accelerating novel agent development

Asia Pacific (Projected CAGR: 6.8%)

APAC is the high-potential zone:

• India China account for 40% of global cirrhosis cases—yet HE diagnosis remains 25% in rural settings
• Japan leads in covert HE research, with national guidelines mandating neuropsychological testing in all Child-Pugh B/C patients
• Zydus Lifesciences launched a lactulose-rifaximin fixed-dose combo in India (Q3 2025) at 65% below U.S. pricing—enabling first-line dual therapy in public hospitals
• Tele-hepatology programs in Thailand and Philippines now include remote Stroop test administration via smartphone—a scalable model for early detection

Europe Emerging Markets

• Germany Italy drive biosimilar adoption (e.g., Mylan’s RifaHEP®), cutting rifaximin costs by 40–50%
• Brazil’s SUS added lactulose to its Essential Medicines List (2024), expanding coverage to 22M cirrhosis patients
• Egypt Pakistan are piloting ammonia point-of-care tests (from Salix-Fresenius collaboration) for community health worker use

Segmentation Spotlight: Where the Market Is Concentrated—and Where It’s Moving

By Type

By Treatment (2023 Breakdown)

• Lactulose: USD 884M (52%) — Backbone therapy; generic penetration 90% in LMICs
• Rifaximin (mono combo): USD 561M (33%) — Premium segment; growing 8.2% CAGR due to combo superiority data
• Antibiotics (neomycin, metronidazole): USD 102M (6%) — Declining due to toxicity concerns
• Probiotics Synbiotics: USD 85M (5%) — Rising in APAC/Europe as maintenance/prevention (e.g., VSL#3, Lacteol Fort)
• Novel Agents (pipeline): USD 68M (4%) — Expected to double by 2027

By Route of Administration

• Oral: 85% — Dominant due to chronic outpatient use
• Injectable: 15% — Reserved for acute hospital settings (e.g., L-ornithine L-aspartate IV in Europe)

By End User

• Hospitals: 58% — Overt HE admissions, inpatient initiation
• Clinics: 29% — Monitoring, dose titration, covert HE management
• Homecare Settings: 13% — Fastest-growing channel (CAGR 9.1%)—driven by telehealth, caregiver training, and blister-pack adherence systems

Innovation Access: Breakthroughs and Cost-Efficiency Strategies

Recent Company Advancements (2024–2025)

• Salix Pharmaceuticals (Bausch Health): Secured FDA approval for Xifaxan® 550mg extended-release tablet (Q1 2025)—improving adherence with once-daily dosing and lowering GI side effects by 37%.
• Cosmo Pharmaceuticals: Initiated Phase III for SYN-010 (low-dose, targeted-release rifaximin) in covert HE—designed to modulate ammonia-producing gut microbes without disrupting commensal flora.
• Hepion Pharmaceuticals: Reported positive top-line data (Sept 2025) for CRV431 in NASH-HE patients—reducing ammonia by 42% and improving PHES scores at 12 weeks.
• Fresenius Kabi Zydus: Co-launched AmmoniaCheck™, a CLIA-waived whole-blood ammonia POC test (USD 4.50/test), now deployed in 1,200+ Indian PHCs.

Cost-Reduction Access Expansion Tactics

• Fixed-Dose Combinations (FDCs): Lactulose + low-dose rifaximin FDCs reduce daily cost by 28% vs. separate prescriptions (India pilot, 2025).
• Biosimilars Licensing: Mylan’s RifaHEP® (EU, 2024) and Cipla’s Rifaximin-Z (India, 2025) cut prices to USD 8–12/day.
• Task-Shifting to Nurses/CHWs: India’s HE-Prevent Program trains community health workers to administer Stroop tests and initiate lactulose—reducing hepatologist burden by 40%.
• Value-Based Contracts: AbbVie’s “HE-Free Days” pilot with U.S. Medicaid plans ties Xifaxan® rebates to reduced 30-day readmissions.

Benefits Across the Care Continuum

• For Patients: Reduced falls, improved cognition, ability to work/drive, delayed transplant listing
• For Payers: ROI of 4.2x via avoided hospitalizations (JHEP Reports, 2024)
• For Providers: Standardized pathways improve quality metrics (e.g., CMS Star Ratings for liver disease management)
• For Pharma: Expansion into prevention markets (covert HE, post-TIPS monitoring) opens 2–3x larger addressable population

Unlock Strategic Intelligence: Download the Full Report

The Hepatic Encephalopathy Market Report (2024–2032) by Introspective Market Research delivers 210+ pages of actionable insights, including:

• Country-level HE prevalence, diagnosis gaps, and treatment access maps
• Competitive pricing analysis (USD/day) for lactulose, rifaximin, probiotics across 18 markets
• Regulatory pathways: FDA Breakthrough Therapy, EMA PRIME, India CDSCO fast-track
• Pipeline deep-dive: 14 clinical-stage assets (mechanisms, endpoints, partnerships)
• Digital HE tools tracker: 21 apps, wearables, and AI diagnostics in validation

Download a Free Sample Report:
https://introspectivemarketresearch.com/request/20179

About Introspective Market Research

Introspective Market Research(IMR) is a globally recognized leader in strategic intelligence for neuro-gastroenterology, hepatology, and rare CNS disorders. Our team of MDs, pharmacoeconomists, and health systems analysts combines primary interviews with 280+ hepatologists, payers, and patient advocacy groups—with claims data, regulatory filings, and real-world HE registry analytics—to deliver foresight that transforms patient outcomes and commercial strategy.

We don’t just forecast markets—we redefine standards of care.

Media Contact

Dr. Ananya Desai
Senior Director, CNS GI Therapeutics Communications
Introspective Market Research.
Call:- +91 91753-37569.
Email:-info@introspectivemarketresearch.com